

Health Innovation Manchester and GSK Joint Working Project: Community Pharmacy Inhaler Review Service

Executive Summary

Health Innovation Manchester and GSK are undertaking Joint Working with the aim of delivering asthma care to patients within a community pharmacy setting. This involves a balance of contributions with the pooling of skills, experience and resources. The project aims to support the delivery of asthma care within this setting in the locality as well as aiming to ensure that the care delivered is implemented within local guidelines. The project will consist of a method to identify uncontrolled asthma patients, who will be invited for an asthma review in community pharmacy. The review will include inhaler technique and an assessment of asthma control, followed by a referral for a medication change if needed. Progress will be tracked with anonymised data and patient questionnaires. Overall project delivery will be overseen by a Project Manager.

The project will run from October 2019 until March 2021 (end date is dependent upon the start date of the patient review service, exact end date to be confirmed).

Key Objectives:

- Demonstrate that a new pathway of asthma care can be delivered within community pharmacy.
- Improve the standard of asthma care in the identified patient cohort resulting in an improvement in asthma control.
- Demonstrate the value of the asthma control test as an aid to decision making in primary care.
- Following the successful delivery of the project, secure commitment from CCGs to commission asthma patient review in community pharmacy across Greater Manchester.
- Through the successful delivery of the project demonstrate the value of collaboration between the NHS, including community pharmacy, and GSK and thus increase the reputation of GSK and build trust with regards to future collaboration.

Intended Benefits

For the Patient	<ul style="list-style-type: none">- Opportunity to have their asthma medication optimised potentially leading to better asthma control and outcomes- Opportunity to have an asthma review at a more convenient time and/or place
For the NHS	<ul style="list-style-type: none">- The potential for reduced healthcare utilisation due to asthma, including primary and secondary care- Increased number of annual asthma QoF reviews, including the difficult to reach patients who are usually exception coded- Opportunity to raise the profile of community pharmacy and the role they can play in delivering asthma care
For GSK	<ul style="list-style-type: none">- Opportunity to optimise medicines, meaning that patients will be stepped up or down in line with BTS/GMMMG Guidelines resulting in the potential use of GSK medicines as well as those of other pharmaceutical companies- Improved corporate reputation amongst local and national stakeholders